Mesoblast, an Australian company that develops stem cell treatments, has agreed to acquire the remaining shares of Angioblast Systems that it doesn't yet own. The acquisition will give Mesoblast exclusive rights to various treatments, including a stem cell treatment that expands umbilical cord blood used in bone marrow transplants among leukemia patients. Mesoblast hopes to get the treatment approved by 2012.

Related Summaries